MGMT and cancer: Hence, dose-dense TMZ regimens including a continuous daily schedule at a dose of 50 mg/m2/d (24), the 7 of 14-day schedule at a dose of 150 mg/m2/d (25) and the 21 of 28-day schedule at a dose of 75 to 100 mg/m2/d (26) were proposed with the idea that they could potentially reduce MGMT level in cancer cells by overwhelming the cells’ ability to synthesize MGMT, and thus might improve TMZ’s therapeutic activity (27).